Hyperpolypharmacy is a predictor of mortality after left ventricular assist device (LVAD) implantation
Background: The prevalence of (hyper)polypharmacy in patients on left ventricular assist device (LVAD) support and its effect on clinical outcomeis unknown. Therefore, we aimed to determine the prevalence of (hyper)polypharmacy in LVAD patients and evaluate its association with mortality and complic...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-12-01
|
Series: | American Heart Journal Plus |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666602222001501 |